Category: CRAL

  • Reducing protein intake could promote healthy aging

    Reducing protein intake could promote healthy aging

    Protein-fortified foods are popping up everywhere, from cereal and coffee to even protein water. But a new review covering over 350 papers on protein restriction and aging—publishing July 31 in the Cell Press journal Cell Press Blue—suggests that consuming less protein could have greater health benefits and could, in some cases, extend lifespan. The authors describe how protein restriction slows aging by improving metabolism, changing how cells respond to nutrients, reducing cellular damage, and preserving healthy cell function.

    “It’s absolutely crystal clear that there are benefits of protein to muscle growth and exercise response of active individuals,” says Dudley Lamming, the paper’s corresponding author, of the University of Wisconsin-Madison. “But because most people are relatively sedentary, many people are likely consuming more protein than they actually need, which probably has negative health consequences.”

    For decades, scientists have known that eating less calories can extend lifespan in many organisms and reduce the risk of age-related diseases like cancer. But maintaining a calorie-restricted diet is difficult for most people.

    Previous studies have found that eating less protein can extend the lifespan of flies and rodents without reducing their calorie consumption. Several recent clinical trials in humans have also shown that reducing protein intake can reduce weight and fat mass and improve fasting blood sugar in humans, even though protein-restricted individuals tend to eat more calories.

    But at the same time, some studies have found that eating more protein could promote weight loss and reduce age-related muscle loss in older adults when paired with exercise. Those findings prompted US authorities to update its dietary guidelines this year, recommending an increase in daily protein intake to 1.2–1.6 grams per kilogram of body weight (0.5–0.7 grams per pound), nearly doubling the previous recommendations.

    With Americans consuming more protein than ever and older adults encouraged to boost their intake, Lamming and his colleague set off to review decades of research on protein restriction and aging. Drawing on more than 350 papers, the team outlined potential mechanisms that consistently emerge across studies and may explain how protein-restricted diets could improve health and promote longevity. These mechanisms suggest that protein restriction slows aging by improving metabolism, changing how cells respond to nutrients, reducing cellular damage, and preserving healthy cell function.

    One of the key players is a hormone called fibroblast growth factor 21 (FGF21), which rises when protein intake is low. FGF21 can increase the body’s energy expenditure, improve blood sugar control, and reduce inflammation. Studies in mice have shown that animals with higher FGF21 levels lived longer than normal mice, and the benefit was more pronounced in male mice than female mice. Eating less protein raises FGF21 levels in humans as well.

    The review also highlights several amino acids, the building blocks of protein, that appear to drive many of these effects, including methionine, isoleucine, and valine. Studies show that consuming too much of these amino acids could trigger biological processes that promote growth, increasing the risk of obesity, inflammation, and other age-related diseases.

    “These studies show that the amount of protein sedentary people are eating today may have negative health consequences, at least at the population level,” Lamming says.

    He adds that while some people, like pregnant women and some older adults, have higher protein needs, for most sedentary adults, protein-fortified food may not provide the health benefits people expect.

    Lamming notes that athletes often consume large amounts of protein without developing metabolic diseases. He suspects that regular exercise, perhaps by using protein to build strong healthy muscles, helps protect them from the negative health effects associated with a protein-rich diet.

    “Recent recommendations have encouraged people to eat more protein, but they’ve also encouraged people to exercise more,” Lamming says. “We probably need to personalize protein recommendations based not just on age, but also on how physically active people are.”

    ###

    This work was supported by the National Institute on Aging, the Wisconsin Partnership Program, and the University of Wisconsin–Madison.

    Cell Press Blue, Knopf et al., “The hallmarks of protein and amino acid restriction in aging and longevity” https://www.cell.com/cell-press-blue/fulltext/S3051-3839(26)00077-0

  • New Study Shows Low-Dose Omega-3 Intake Does Not Raise Atrial Fibrillation Risk

    New Study Shows Low-Dose Omega-3 Intake Does Not Raise Atrial Fibrillation Risk

    A new meta-analysis led by researchers from the Fatty Acid Research Institute (FARI) provides the clearest picture to date of the relationship between omega-3 fatty acid supplementation and atrial fibrillation (AF), helping resolve years of confusion generated by earlier reports.

    Published in Circulation: Arrhythmia and Electrophysiology, the study, led by Dr. Nada Abuknesha, PhD, an Associate Scientist at FARI, analyzed data from 35 randomized controlled trials involving 114,592 participants—more than four times the number of studies included in previous meta-analyses. Researchers also incorporated unpublished trial data and previously unavailable safety information to provide the most comprehensive assessment of AF risk to date.

    The Key Finding

    The analysis found that low-dose omega-3 supplementation (less than 1,500 mg/day EPA+DHA) was not associated with an increased risk of AF, even among individuals at elevated cardiovascular risk.

    In contrast, only in the setting of high-dose omega-3 therapy (>1,500 mg/day, typically prescription-strength formulations) used in patients with established cardiovascular disease was AF risk modestly increased (i.e., the absolute risk increase was 0.8%).

    “Our findings show that the relationship between omega-3s and atrial fibrillation is much more nuanced than previous headlines suggested,” said William S. Harris, PhD, President of the Fatty Acid Research Institute (FARI) and senior author on the study. “For the vast majority of people taking nutritional doses of omega-3s, these data should provide reassurance that there is no meaningful increase in atrial fibrillation risk.”

    Addressing a Long-Standing Controversy

    In recent years, several meta-analyses suggested that omega-3 supplements may increase the risk of AF. However, those reports included no more than eight randomized trials, focused primarily on cardiovascular outcome studies, and did not account for many eligible trials where AF data were available but unpublished.

    The new FARI-led analysis expanded the evidence base substantially by:

    • Including 35 randomized controlled trials involving 114,592 participants
    • Incorporating 15 trials containing previously unpublished AF data
    • Including studies reporting zero AF events, reducing publication bias
    • Evaluating risk according to both omega-3 dose and underlying cardiovascular risk, providing a more clinically meaningful interpretation of the evidence.

    Putting the Findings Into Clinical Context

    Researchers emphasize that even among high-risk cardiovascular patients receiving prescription-level omega-3 doses, the observed increase in AF should be weighed against the well-established cardiovascular benefits demonstrated in major clinical trials.

    For example, previous studies of high-dose EPA have shown reductions in heart attacks, stroke, and other major cardiovascular events that substantially outweigh the small increase in atrial fibrillation risk.

    “The decision to take or discontinue omega-3 supplements should be a discussion between a patient and his/her healthcare provider,” said Harris. “What this study does is provide clinicians with better guidance on which patients may benefit from closer monitoring when using high-dose omega-3 therapies while reassuring consumers that it is safe to consume omega-3 fatty acids from foods and dietary supplements.”

    Implications for Consumers and Clinicians

    The findings reinforce an important distinction between:

    • Nutritional omega-3 supplementation (typically 500-1,500 mg/day), commonly used to support general health and cardiovascular wellness.
    • Pharmacological omega-3 therapy (typically 2-4 grams/day), prescribed for individuals with elevated triglycerides or established cardiovascular disease.

    The authors emphasize that AF risk profiles should be evaluated separately for each category, as nutritional doses do not carry the same clinical implications as higher pharmacological doses.

    About the Study

    The study, Effects of Omega-3 Fatty Acid Treatment on Risk for Atrial Fibrillation: An Updated Meta-Analysis of 35 Trials Including 114,592 Individuals, was led by researchers from the Fatty Acid Research Institute in collaboration with investigators from institutions worldwide. The systematic review included published and unpublished randomized clinical trial data and represents the largest analysis to date examining omega-3 supplementation and incident AF.

    Disclaimer: This publication from FARI was commissioned by the Global Organization for EPA and DHA Omega-3s (GOED). GOED did not have any input into the study design, data analysis or interpretation.

    About the Fatty Acid Research Institute (FARI)

    The Fatty Acid Research Institute (FARI) is a non-profit research and education foundation created by William S. Harris, PhD, FASN. Dr. Harris is also the founder of OmegaQuant Analytics. FARI was founded in order to accelerate discovery of the health effects of fatty acids, most notably, the long chain omega-3 fatty acids EPA and DHA. FARI researchers and scientists focus single-mindedly on publishing high-quality research studies on the multiple relationships between fatty acid levels and human (and animal) health outcomes. These studies will help improve the ability to predict risk for disease, and more importantly, suggest ways to reduce risk by changing diets and/or supplementation regimens. www.faresinst.org

    About Dr. Bill Harris:

    Dr. Harris has been a leading researcher in the omega-3 fatty acid field for more than 40 years. He has nearly 400 scientific papers on fatty acids and health, the vast majority on omega-3. He has been on the faculty of three medical schools (Universities of Kansas, Missouri (at Kansas City), and South Dakota) and has received 5 NIH grants to study omega-3. He was the co-author on three AHA statements on fatty acids and heart health. As the co-inventor of the Omega-3 Index (and other omega-3 blood tests) and founder of OmegaQuant Analytics, Dr. Harris has been ranked among the top 2% of scientists worldwide based on the impact of his research. Dr. Harris publications: https://www.ncbi.nlm.nih.gov/myncbi/1fAOCyhA-fcQV/bibliography/public/

  • Vitamin C Status Linked to Measures of Healthier Brain Aging

    Vitamin C Status Linked to Measures of Healthier Brain Aging

    Could something as simple as vitamin C help support a healthier aging brain? In a study of more than 2,000 older adults in Japan, researchers found that people with lower vitamin C levels in their blood also tended to have less gray matter and weaker connections in a key brain network involved in memory, attention, and other cognitive functions. The findings were published by researchers from Haurka Nagaya of Hirosaki University in PLOS One.

    Earlier studies have suggested that people who consume more vitamin C are less likely to experience cognitive impairment as they get older. However, relatively little research has examined whether vitamin C levels measured directly in the blood are associated with physical changes in the brain.

    To investigate that question, the researchers analyzed magnetic resonance imaging (MRI) scans and blood plasma samples from 2,044 Japanese adults over the age of 64.

    Using the MRI scans, they measured the volume of gray matter and white matter in each participant’s brain while accounting for differences in overall brain size. They also examined connectivity within the default mode network, a group of interconnected brain regions that plays an important role in attention, autobiographical memory, and other cognitive functions.

    Lower Vitamin C Linked to Smaller Gray Matter

    After adjusting for factors that can also influence brain health, including age, education level, and physical activity, the researchers found a consistent pattern. Participants with lower plasma vitamin C levels tended to have reduced gray matter volume and weaker connectivity within the default mode network.

    The results suggest that maintaining healthy vitamin C levels could potentially help support cognitive function and healthy brain aging. However, the researchers emphasize that this was an observational study, meaning it cannot determine whether vitamin C directly causes these differences in brain structure or function. More research will be needed to uncover the biological mechanisms behind these statistical associations.

    One of the study authors Tomohiro Shintaku stated “Our study demonstrates that higher plasma vitamin C levels are associated with better preserved structural connectivity of the default mode network (DMN), a key brain network involved in cognitive function. This finding generates the exciting hypothesis that a diet rich in vitamin C might play a supportive role in maintaining brain health and mitigating age-related cognitive decline in older adults.”

    He continued: “What I found most fascinating about this research is that we were able to detect these subtle but significant associations between a single nutritional factor and large-scale brain networks by utilizing a robust, community-based cohort of over 2,000 older adults. It truly highlights the potential impact of our everyday dietary habits on our brain structures.”